Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Spine BioPharma Completes Enrollment for Phase 3 Trial of SB-01 for Chronic Low Back Pain
Details : SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. It is being developed for chronic low back pain in degenerative disc disease.
Brand Name : SB-01
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 24, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Recipient : Ensol BioSciences
Deal Size : $155.0 million
Deal Type : Agreement
Spine BioPharma Signs with Ensol BioSciences to Expand Indications for SB-01 Injection
Details : Spine BioPharma acquired the right to develop and commercialize SB-01, excluding Korea. It is being evaluated for the treatment of pain-related disability, associated with Degenerative Disc Disease.
Brand Name : SB-01
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Recipient : Ensol BioSciences
Deal Size : $155.0 million
Deal Type : Agreement
Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study
Details : SB-01 is a 7-amino acid peptide that binds to and antagonizes TGFβ1 activity. TGFβ1 is an inflammatory cytokine which is often highly expressed in the degenerated discs.
Brand Name : SB-01
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 07, 2022
Spine BioPharma Initiating U.S. Phase 3 Clinical Study
Details : SB-01 is a 7-amino acid peptide that binds to and antagonizes TGFβ1 activity, is the first pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with DDD.
Brand Name : SB-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 11, 2022
Lead Product(s) : SB-01
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Viscogliosi Bros.
Deal Size : $13.0 million
Deal Type : Series B Financing
Spine BioPharma Completes Series B Financing
Details : The company intends to use the financing to support further development of SB-01 For Injection "SB-01" (formerly referred to as Remedisc™), a first-in-class therapeutic for the treatment of degenerative disc disease.
Brand Name : Remedisc
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 28, 2022
Lead Product(s) : SB-01
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Viscogliosi Bros.
Deal Size : $13.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?